%0 Journal Article
%A Corma-Gomez, Anaïs
%A Fernandez-Fuertes, Marta
%A Garcia, Estefania
%A Fuentes-Lopez, Ana
%A Gomez-Ayerbe, Cristina
%A Rivero-Juarez, Antonio
%A Dominguez, Carmen
%A Santos, Marta
%A Viñuela, Laura
%A Palacios, Rosario
%A Real, Luis M
%A Rivero, Antonio
%A Macias, Juan
%A Pineda, Juan A
%A Garcia, Federico
%T Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.
%D 2022
%U http://hdl.handle.net/10668/22132
%X The aim of this study was to assess the immunogenicity of SARS-CoV-2 available vaccines among people living with HIV (PLWH) after a complete vaccination scheme, and determine predictors of seroconversion. This multicentre prospective cohort study included 420 PLWH who had received a standard immunization, either with mRNA or adenoviral-vectored COVID-19 vaccines. Antibody response was evaluated within 1 to 2 months after the last dose of the vaccine with a quantitative determination of antitrimeric spike protein-specific IgG antibodies and IgG neutralizing antibodies. Overall, 384 of 420 PLWH (91%) showed antibody response to vaccination. Seroconversion was observed in 308 of 326 individuals with cluster of differentiation 4 (CD4) counts ≥350 cells/mm3 (95%), 55 of 61 PLWH with 200 to 349 cells/mm3 (90%), and 21 of 33 PLWH with CD4 counts  HIV-related immunosuppression impairs the antibody response to SARS-CoV-2 vaccines. Specific vaccination schemes should be urgently tailored in this setting, particularly in patients with CD4 cell counts
%K CD4 T-cell counts
%K Humoral response
%K People living with HIV
%K SARS-CoV-2
%K Vaccine
%K Área de Gestión Sanitaria Sur de Sevilla
%~